Lymphoma Trial, Recruiting (NCT06919393)

Lymphoma Trial, Recruiting NCT06919393 Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS Condition: Lymphoma

Printed from Voxsanity (voxsanity.com.au) — NCT06919393 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lymphoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are willing and able to give their informed consent to participate in the study
People who have been newly diagnosed with, or have had one or more relapses of, a type of blood cancer called B-cell acute lymphoblastic leukaemia (B-ALL), whether it started in the blood or spread from another source
People whose cancer does not carry certain specific genetic changes known as BCR-ABL1 t(9;22), TCF3-PBX1 t(1;19), or MLL-AF4 t(4;11)
People aged 18 years or older
People whose clinical records and data are available for use in the study

Who may not be able to join:

People under 18 years of age
People whose B-ALL does carry any of the specific genetic changes mentioned above: BCR-ABL1 t(9;22), TCF3-PBX1 t(1;19), or MLL-AF4 t(4;11)
People whose blood or bone marrow samples contain a low proportion of cancer cells (less than 70%) may be excluded from certain parts of the molecular testing, though not necessarily from all parts of the study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 19 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Giovanni Martinelli, Prof, IRST IRCCS

Phone: +39 0543739100

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06919393

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase: Not Applicable

Status: Recruiting

Condition: Lymphoma

Trial contact: +39 0543739100

More information: https://clinicaltrials.gov/study/NCT06919393

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are willing and able to give their informed consent to participate in the study
People who have been newly diagnosed with, or have had one or more relapses of, a type of blood cancer called B-cell acute lymphoblastic leukaemia (B-ALL), whether it started in the blood or spread from another source
People whose cancer does not carry certain specific genetic changes known as BCR-ABL1 t(9;22), TCF3-PBX1 t(1;19), or MLL-AF4 t(4;11)
People aged 18 years or older
People whose clinical records and data are available for use in the study

Who may not be able to join:

People under 18 years of age
People whose B-ALL does carry any of the specific genetic changes mentioned above: BCR-ABL1 t(9;22), TCF3-PBX1 t(1;19), or MLL-AF4 t(4;11)
People whose blood or bone marrow samples contain a low proportion of cancer cells (less than 70%) may be excluded from certain parts of the molecular testing, though not necessarily from all parts of the study (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 19 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Registry

ClinicalTrials.gov

Start date

23 October 2019

Est. completion

1 January 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Biological characterization for B-ALL Ph-/-/- subgroup identification

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov